Navigation Links
Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
Date:5/1/2008

Bank $35,749 $32,218 11.0% 136,148 126,216 7.9%

Red Cell $12,120 $11,301 7.2% 46,377 43,406 6.8%

$88,299 $74,237 18.9% $337,744 $296,593 13.9%

Patient:

Surgical/Diagnostic $21,178 $17,254 22.7% 72,085 66,552 8.3%

OrthoPAT $9,179 $8,383 9.5% 34,301 30,515 12.4%

$30,357 $25,637 24.0% $106,386 $97,067 9.6%

Subtotal $118,656 $99,874 18.8% $444,130 $393,660 12.8%

Equipment $10,527 $7,022 49.9% $32,813 $22,229 47.6%

Software & Services $9,556 $10,023 (4.7%) 39,498 33,718 17.1%

Net Revenues $138,739 $116,919 18.7% $516,440 $449,607 14.9%

Consolidated Balance Sheets

Period ending

03/29/08 03/31/07

Assets

Cash & cash equivalents $133,553 $229,227

Accounts receivable, net $120,252 $91,832

Inventories, net $65,388 $61,797

Other current assets $32,881 $20,815

Total current assets $352,074 $403,671

Net PP&E $116,484 $90,775

Other assets $129,198 $78,289

Total assets $597,756 $572,735

Period ending

03/29/08 03/31/07

Liabilities & Stockholders' Equity

S/T debt & current maturities $6,326 $22,201

Other current liabilities 89,391 $59,816

Total current liabilities 95,717 82,017
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 1RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 2RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 3RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 4Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 1Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 3
Other Medicine Technology:Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 3Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 4Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 5Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 6Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 2Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 3Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 4Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 5Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 6